Published in
Wiley, Journal of Surgical Oncology, 1(98), p. 34-41, 2008
DOI: 10.1002/jso.21063
Links
Tools
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study
,
Yih-Leong Chang,
Chih-Hung Hsu,
Yu-Chieh Tsai,
Yung-Chie Lee,
Jason Chia-Hsien Cheng,
Feng-Ming;Lin Chia-Chi;Lee Jang-Ming;Chang Yih-Leong;Hsu Chih-Hung;Tsai Yu-Chieh;Lee Yung-Chie;Cheng Jason Hsien Hsu
Full text: Download
Abstract
Background and Objectives: To investigate the impact of using paclitaxel in chemoradiation on locally advanced esophageal squamous cell carcinoma ( SCC) treated with or without surgery. Methods: Of 127patients with AJCC stages II–III esophageal SCC undergoing definitive chemoradiation ( DefCRT, nà‚¼ 44) or neoadjuvant chemoradiation plus surgery (NeoCRTà€€ 254;S, nà‚¼83), 57recei ved chemotherapy with paclitaxel and cisplatin (TP), and 70 received 5- fluorouracil and cisplatin (PF). Three-year local progression-free survival (LPFS), distant metastasis- free survival, overall survival, and prognostic factors were retrospectively analyzed. Results: The median survival was 30 months. Pathological complete response rate was 41% and 27% with TP and PF, respectively (Pà‚¼0.19). NeoCRTthorn;S achieved significantly higher LPFS than DefCRT (71% vs. 39%, P